2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-165634
    (R)-Azelnidipine 722455-08-5 98%
    (R)-Azelnidipine is a highly lipophilic Calcium Channel antagonist with high affinity for vascular walls and antihypertensive activity. (R)-Azelnidipine shows potential for use in cardiovascular disease research.
    (R)-Azelnidipine
  • HY-167168
    (S)-Azelnidipine 722455-09-6 98%
    (S)-Azelnidipine is a calcium channel (Calcium Channel) blocker and the S-isomer of Azelnidipine, with potential for use in cardiovascular disease research.
    (S)-Azelnidipine
  • HY-167203
    AJG049 free base 195991-49-2 98%
    AJG049 free base is a calcium channel (Ca2+ channel) antagonist. AJG049 free base regulates vascular relaxation, reduces cardiac load, and improves cardiac perfusion by binding to the binding site of L-type calcium channels, specifically Diltiazem (HY-B0632). AJG049 free base can be used in cardiovascular disease research.
    AJG049 free base
  • HY-167636
    7-Hydroxy ropinirole bromide 81654-57-1 98%
    7-Hydroxy ropinirole (SK&F 89124) bromide is a potent and highly selective DA2 receptor agonist, and a derivative of N,N-di-n-propyldopamine (DPDA). In isolated perfused rabbit ear artery models, 7-Hydroxy ropinirole (bromide) exerts its DA2 agonist effects by inhibiting neurotransmitter release or sympathetic nerve-induced responses. It shows potential for research in the fields of cardiovascular and neurological diseases.
    7-Hydroxy ropinirole bromide
  • HY-167657
    Tizolemide 56488-58-5 98%
    Tizolemide is a sulphonamide diuretic compound that has alkaline properties and is cleared by a tubular transport system. Tizolemide induces changes of passive transport components across the basolateral membrane of isolated frog skin.
    Tizolemide
  • HY-167668
    Tipindole 7489-66-9 98%
    Tipindole is a serotonin antagonist. Tipindole can be used in depression research.
    Tipindole
  • HY-167681
    Carprazidil 68020-77-9 98%
    Carprazidil (Ro 12-4713) is a potent vasodilator with activity in suppressing severe hypertension and mild heart failure. The use of carprazidil may lead to sodium retention and increased heart rate, requiring increased doses of diuretics or beta-blockers in some cases. Carprazidil and mecycline may both cause hirsutism, limiting their long-term use in women. Carprazidil did not cause adverse side effects on hematological parameters, liver, or kidney function.
    Carprazidil
  • HY-16768R
    Fevipiprant (Standard) 872365-14-5 98%
    Fevipiprant (Standard) is the analytical standard of Fevipiprant. This product is intended for research and analytical applications. Fevipiprant (QAW039, NVP-QAW039) is s an orally active, selective, reversible prostaglandin D2 (DP2) receptor antagonist with an Kd value of 1.14 nM. Fevipiprant has the potential for the research of bronchial asthma.
    Fevipiprant (Standard)
  • HY-167743
    Platelet aggregation-IN-2 41552-94-7 98%
    Platelet aggregation-IN-2 is an anti-platelet aggregation agent with significant anticoagulant activity. Platelet aggregation-IN-2 can inhibit platelet aggregation reaction and reduce the risk of thrombosis. The application of Platelet aggregation-IN-2 can potentially be used for the prevention and suppression of cardiovascular diseases.
    Platelet aggregation-IN-2
  • HY-16774R
    Vericiguat (Standard) 1350653-20-1 98.87%
    Vericiguat (Standard) is the analytical standard of Vericiguat. This product is intended for research and analytical applications. Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
    Vericiguat (Standard)
  • HY-167848
    DMP-728 free base 153345-74-5 98%
    DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time.
    DMP-728 free base
  • HY-167866
    Ersentilide 125279-79-0 98%
    Ersentilide, a benzamide derivative, is a is a β1-adrenoceptor antagonist and Ikr blocker. Ersentilide is effective in several intact animal models of arrhythmia.
    Ersentilide
  • HY-167867
    Utibaprilat 109683-79-6 98%
    Utibaprilat (FPL 63674XX) is a ACE inhibitor that is a major degradation product of Utibapril (HY-101681).
    Utibaprilat
  • HY-167886
    GA 0113 200639-61-8 98%
    GA 0113 is a potent and orally active angiotensin II (Ang II) AT1-receptor antagonist. GA 0113 inhibits the Ang II (HY-13948)-induced pressor response with ID50 of 0.032 mg/kg and dose-dependently increases plasma renin activity for 48 h.
    GA 0113
  • HY-168367
    2-Hydroxyethylflurazepam 20971-53-3 98%
    2-Hydroxyethylflurazepam (compound II) is a metabolite of Flurazepam.
    2-Hydroxyethylflurazepam
  • HY-168770
    Cl-Necrostatin-1 862377-51-3 98%
    Cl-Necrostatin-1 is a RIPK1 inhibitor. Cl-Necrostatin-1 can also inhibit TNF-α-induced necroptosis in Jurkat cells deficient in Fas-associated death domain protein (FADD; EC50 = 180 nM), a modification that prevents caspase activation in response to death-domain receptor signaling. Cl-Necrostatin-1 can also reduce infarct size in a mouse model of middle cerebral artery occlusion (MCAO). Cl-Necrostatin-1 is used for research in cardiovascular and cerebrovascular diseases.
    Cl-Necrostatin-1
  • HY-168801
    13,14-Dihydro-15-keto-tetranor prostaglandin F1β 23015-45-4 98%
    13,14-Dihydro-15-keto-tetranor prostaglandin F1β is a major urinary metabolite of Prostaglandin E2 (HY-101952).
    13,14-Dihydro-15-keto-tetranor prostaglandin F1β
  • HY-168802
    9-Keto tafluprost 261179-75-3 98%
    9-Keto tafluprost is a derivative of Tafluprost (HY-B0600). Tafluprost is an anti-glaucoma prostaglandin (PG) analog.
    9-Keto tafluprost
  • HY-169114
    Goxalapladib 412950-27-7 98%
    Goxalapladib is a 5-HT6 receptor modulator that blocks lipoprotein-associated phospholipase A2 (Lp-PLA2) activity. Goxalapladib is promising for research of atherosclerosis-associated cardiovascular diseases.
    Goxalapladib
  • HY-169128
    Clopipazan 60085-78-1 98%
    Clopipazan is a potent antipsychotic agent.
    Clopipazan
Cat. No. Product Name / Synonyms Application Reactivity